Short-term infusion of ultralow-dose dopamine in an adult horse with acute kidney injury: A case report.
Abdominal pain
Acute kidney injury
Ultralow-dose dopamine
Journal
Veterinary and animal science
ISSN: 2451-943X
Titre abrégé: Vet Anim Sci
Pays: Netherlands
ID NLM: 101694897
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
24
12
2020
revised:
23
02
2021
accepted:
28
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Much is known regarding a good prognosis of acute kidney injury (AKI) is achieved with adequate, intensive, and early treatment, which leads to acceleration of the renal blood flow rate and associated urination. Low-dose dopamine (1 to 5 μg/kg bwt per min) is a treatment option for AKI in humans but remains controversial for use in horses because of the lack of extensive clinical trial data. A 19-year-old Westfalen horse gelding was referred to the Animal Medical Center with a 1-hour history of mild abdominal pain and anorexia after dressage exercise for 1 hour. Since elevated serum levels of blood urea nitrogen (BUN) and creatinine were found on days 4 and 5, the horse was diagnosed with AKI. In addition to basic hydration therapy with lactated Ringer's solution, we decided to use ultralow-dose dopamine because of the possibilities of the upregulation of dopamine receptors in the affected kidney and general large animal specificity of drug doses. Infusions with 0.04 and 0.02 μg/kg bwt per min for 1 hour on days 6 and 7, respectively, were effective in decreasing serum levels of BUN and creatinine accompanied with a diuretic effect. Thus, short-term infusion of ultralow-dose dopamine may be useful in controlling the renal blood flow rate and clinical conditions in horses with AKI.
Identifiants
pubmed: 33912729
doi: 10.1016/j.vas.2021.100176
pii: S2451-943X(21)00012-0
pmc: PMC8066775
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100176Informations de copyright
© 2021 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors have declared that no conflict of interest exists.
Références
Clin Pharmacokinet. 1990 May;18(5):381-408
pubmed: 2185908
Vet Clin North Am Equine Pract. 2007 Dec;23(3):577-91, v-vi
pubmed: 18061851
Am J Hypertens. 1991 Jun;4(6):494-9
pubmed: 1651737
Vet Clin North Am Equine Pract. 1987 Dec;3(3):585-615
pubmed: 3322528
Neuroscience. 2017 Jun 3;352:9-18
pubmed: 28389378
Clin Neurophysiol. 2010 Jul;121(7):996-7
pubmed: 20231112
J Vet Intern Med. 1991 Jul-Aug;5(4):211-8
pubmed: 1941755
J Vet Emerg Crit Care (San Antonio). 2011 Dec;21(6):648-57
pubmed: 22316258
Equine Vet J. 2018 Jan;50(1):104-110
pubmed: 28710899
Ann Intern Med. 2005 Apr 5;142(7):510-24
pubmed: 15809463
Equine Vet J. 2019 Mar;51(2):147-153
pubmed: 30048005
J Am Vet Med Assoc. 2006 Feb 15;228(4):572-7
pubmed: 16478436
Am Fam Physician. 2000 Apr 1;61(7):2077-88
pubmed: 10779250
Clin Pharmacol Ther. 1986 Dec;40(6):610-4
pubmed: 3780122
Am J Vet Res. 1988 Jul;49(7):1173-8
pubmed: 3421539
Mod Vet Pract. 1984 May;65(5):A26-9
pubmed: 6738502
Equine Vet J Suppl. 1989 Jun;(7):124-8
pubmed: 9118094
Antimicrob Agents Chemother. 1999 May;43(5):1003-12
pubmed: 10223907
Kidney Int. 2006 May;69(9):1669-74
pubmed: 16572117